4.60
-0.135(-2.85%)
Currency In USD
| Previous Close | 4.73 |
| Open | 4.74 |
| Day High | 4.75 |
| Day Low | 4.59 |
| 52-Week High | 6.71 |
| 52-Week Low | 2.46 |
| Volume | 177,047 |
| Average Volume | 890,903 |
| Market Cap | 582.91M |
| PE | -32.82 |
| EPS | -0.14 |
| Moving Average 50 Days | 4.13 |
| Moving Average 200 Days | 3.91 |
| Change | -0.14 |
If you invested $1000 in Organogenesis Holdings Inc. (ORGO) since IPO date, it would be worth $471.28 as of August 18, 2025 at a share price of $4.595. Whereas If you bought $1000 worth of Organogenesis Holdings Inc. (ORGO) shares 5 years ago, it would be worth $1,041.95 as of August 18, 2025 at a share price of $4.595.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
GlobeNewswire Inc.
Jul 22, 2025 8:05 PM GMT
CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation
GlobeNewswire Inc.
Jul 15, 2025 1:00 PM GMT
CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and
Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness
GlobeNewswire Inc.
Apr 11, 2025 8:05 PM GMT
Organogenesis recommends CMS also implement an integrated coverage and payment policyCANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, m